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Abstract: Over the last decades, a better understanding of breast cancer heterogeneity 
provided tools for a biologically based personalization of anticancer treatments. In particular, 
the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells 
provided a specific target in these HER2-positive tumors. The development of the monoclonal 
antibody trastuzumab, and its approval in 1998 for the treatment of patients with metastatic 
disease, radically changed the natural history of this aggressive subtype of breast cancer. These 
findings provided strong support for the continuous research in targeting the HER2 pathway 
and implementing the development of new anti-HER2 targeted agents. Besides trastuzumab, a 
series of other anti-HER2 agents have been developed and are currently being explored for the 
treatment of breast cancer patients, including those diagnosed with early-stage disease. Among 
these agents, neratinib, an oral tyrosine kinase inhibitor that irreversibly inhibits HER1, HER2, 
and HER4 at the intracellular level, has shown promising results, including when administered 
to patients previously exposed to trastuzumab-based treatment. This article aims to review the 
available data on the role of the HER2 pathway in breast cancer and on the different targeted 
agents that have been studied or are currently under development for the treatment of patients 
with early-stage HER2-positive disease with a particular focus on neratinib.
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Introduction
Despite early diagnosis and the availability of more active treatments, breast cancer 
remains a major public health problem.1 To date, early-stage breast cancer is treated 
with curative intent by surgery with or without adjuvant treatments, including chemo-
therapy, endocrine therapy, targeted agents, and radiotherapy.2–4 However, ~20%–30% 
of women will relapse, despite optimal adjuvant therapies.5,6 Furthermore, these treat-
ments and, particularly, chemotherapy are associated with significant toxicities that 
can alter the short- and long-term quality of life of cancer survivors.7 This underlies 
an unmet need to implement more effective therapies with acceptable toxicity profile 
for breast cancer patients with early-stage disease.
Over the last decades, a better understanding of breast cancer heterogeneity 
provided tools for a biologically based personalization of treatments.8 In particular, the 
overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells 
is related to a distinctive molecular signature as compared to HER2-negative tumors.9,10 
Indeed, HER2-positive breast cancers are poorly differentiated and characterized 
by having high grade, high rates of cell proliferation and lymph node involvement 
with a relative resistance to chemotherapies, and a greater likelihood of developing 
distant metastases.8 Interestingly, the expression of the HER2 protein in tumor cells 
provided a specific target in these HER2-positive tumors. The development of the 
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monoclonal antibody trastuzumab and its approval in 1998 
for the treatment of patients with metastatic disease radi-
cally changed the natural history of this subtype of breast 
cancer.11,12 These findings provided strong support for the 
continuous research in targeting the HER2 pathway and 
implementing the development of anti-HER2 targeted agents 
not only in the metastatic setting but also in the early setting.13 
Chemotherapy plus 1 year of trastuzumab is the current 
standard of care for patients with early-stage HER2-positive 
breast cancer.2–4 Besides trastuzumab, a series of other anti-
HER2 agents have been developed and are currently being 
explored for the treatment of breast cancer patients, including 
those diagnosed with early-stage disease. This article aims to 
review the available data on the role of the HER2 pathway in 
breast cancer and on the different targeted agents that have 
been studied or are currently under development for the 
treatment of patients with early-stage HER2-positive disease 
with a particular focus on neratinib.
HER2 pathway in breast cancer
The HER (ErbB) receptor family includes HER1 (ErbB1 
or EGFR), HER2 (ErbB2, HER2/neu), HER3 (ErbB3), and 
HER4 (ErbB4) that act mechanistically through tyrosine 
kinases.14 The HER receptor comprises extracellular, trans-
membrane, and intracellular domains. Eleven ligands are 
known to bind to the HER receptors (HER1, 3, and 4), which 
expose the dimerization domain and facilitate homo- and 
heterodimerization. In contrast, HER2 does not have a known 
ligand and adopts a constantly exposed dimerization domain 
with potent formation of homodimers.15 Dimerization results 
in the activation of the phosphoinositide 3-kinase (PI3K) and 
of the mitogen-activated protein kinase downstream signal-
ing pathways with subsequent promotion of cell survival 
and proliferation.16
Targeting HER2 may encounter de novo or acquired 
resistances that are not yet fully elucidated. The available 
knowledge of de novo resistance describes phosphatase 
and tensin homolog (PTEN) deficiencies, PI3K mutation, 
loss of p27, and HER2 cleavage or allosteric hindrance.17–21 
Acquired resistance occurs secondary to the increased acti-
vation of insulin-like growth factor 1 (IGFR1) and c-Met 
with enhanced release of the HER ligands and activation 
of downstream signaling.21–23 The presence of HER2 muta-
tions may be another possible mechanism of resistance 
to anti-HER2 treatments.24,25 The potential development 
of resistance to anti-HER2 targeted agents represents an 
important rationale for implementing the dual targeting of 
the HER2 pathway.
Targeted agents for the treatment 
of HER2-positive early-stage breast 
cancer
The successful development of trastuzumab validated the 
treatment approach of targeting HER2. The following three 
other anti-HER2 targeted agents have been subsequently 
developed: lapatinib, pertuzumab, and T-DM1. Even more 
recently, a better understanding of the mechanisms of resis-
tance to anti-HER2 therapy has led to the development of 
novel therapeutic agents such as neratinib.
Adjuvant setting
Trastuzumab is the first and so far the only targeted agent 
approved for the adjuvant treatment of patients with early-
stage HER2-positive breast cancer.2,4 The benefit of adding 
trastuzumab to chemotherapy was evaluated in the following 
five main randomized studies: HERA,26–29 NSABP-B31 and 
NCCTG N9831,30–32 BCIRG 006,33,34 and FNCLCC-PACS 
0435 trials. Among these studies, the joint analysis of two 
major North American Cooperative Group trials (NSABP B31 
and NCCTG N9831) established the superiority of combining 
chemotherapy (doxorubicin plus cyclophosphamide followed 
by paclitaxel) with trastuzumab over the arms that did not 
contain the anti-HER2 agent, with the largest benefit shown 
with concurrent administration of taxanes and trastuzumab.36 
Although with a more strict patient selection and close car-
diac assessment the incidence of trastuzumab-related cardiac 
events has been reduced over the past years, cardiotoxicity 
remains a significant problem in clinical practice.37 Hence, 
trastuzumab was also developed and showed important 
efficacy results when combined with nonanthracycline-
based regimens as in the BCIRG 006 trial.33,34 Therefore, in 
patients with cardiac risk factors, the use of this regimen can 
now be considered to overcome any potential cardiac side 
effects.38 The HERA trial confirmed that the standard dura-
tion of adjuvant trastuzumab is 12 months.28,29 A Cochrane 
review that included eight randomized control trials with 
11,991 patients with HER2-positive tumors confirmed the 
superiority of trastuzumab-containing regimens in terms of 
both disease-free survival (DFS; hazard ratio [HR] 0.60; 95% 
confidence intervals [CIs] 0.50–0.71; P,0.0001) and overall 
survival (OS; HR 0.66; 95% CI 0.57–0.77; P,0.00001).39 
Trastuzumab administration was associated with a significant 
increased risk of congestive heart failure (risk ratio [RR] 5.11; 
90% CI 3.0–8.7; P,0.00001) and left ventricular ejection 
fraction decline (RR 1.8; 90% CI 1.4–2.5; P=0.0008).39 Nev-
ertheless, in more recent studies, with a strict patient selec-
tion and close cardiac assessment, the risk of cardiac events 
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with the use of trastuzumab-based regimens has decreased 
significantly.37 As shown in the HERA trial, the majority of 
cardiac events occurred during treatment and were reversible 
in ~80% of the cases.40
If trastuzumab is a monoclonal antibody that interferes 
with HER2 outside of the cell, lapatinib is an oral tyrosine 
kinase inhibitor that reversibly inhibits both HER1 and HER2 
at the intracellular level.41 Lapatinib has been investigated 
in two trials of patients with HER2-positive early-stage 
breast cancer.13
The TEACH study compared lapatinib with placebo 
in 3,147 trastuzumab-naive patients and failed to show a 
statistically significant difference in DFS (HR 0.83; 95% 
CI 0.7–1.0; P=0.053).42,43 The central review of HER2 
status revealed that only 79% of the randomized patients 
were actually HER2 positive. In this group of patients, an 
improved DFS was observed with the use of lapatinib (HR 
0.82; 95% CI 0.7–1.0; P=0.04). Treatment-related grade 
3–4 toxicities included diarrhea (6%), rash (5%), and hepa-
tobiliary disorders (2%). Of note, in this trial, the level of 
HER2 positivity was specified according to the cutoff used 
for trastuzumab approval.
The ALTTO study investigated the efficacy of lapatinib 
alone, the sequence of trastuzumab followed by lapatinib, 
or the dual anti-HER2 blockade (lapatinib plus trastu-
zumab) as compared to standard trastuzumab for 1 year in 
8,381 patients.44 At interim analysis, due to futility in dem-
onstrating noninferiority of lapatinib versus trastuzumab, 
the lapatinib arm was closed and trastuzumab was offered 
to disease-free patients. As compared to trastuzumab alone, 
dual anti-HER2 blockade with lapatinib and trastuzumab 
was not associated with a significant improved DFS (HR 
0.84; 95% CI 0.7–1.02; P=0.048) at the 0.025 significance 
level foreseen in the statistical analysis plan of the study. As 
compared with patients treated with trastuzumab, those who 
underwent lapatinib experienced more diarrhea, cutaneous 
rash, and hepatic toxicity.44
Pertuzumab is a monoclonal antibody that inhibits the 
HER2–HER3 heterodimerization.45 Pertuzumab had been 
demonstrated to significantly improve OS by 15.7 months 
in the metastatic setting when added to a regimen contain-
ing docetaxel plus trastuzumab.46 In the adjuvant setting, 
the Phase III APHINITY trial (NCT01358877) is currently 
evaluating the benefit of its addition to trastuzumab. A press 
release on March 1, 2017, confirmed a significant improve-
ment in invasive DFS (iDFS) with the addition of pertuzumab 
to trastuzumab in patients with early-stage HER2-positive 
breast cancer. Full results of the study are expected to be 
reported at the 2017 American Society of Clinical Oncology 
(ASCO) Annual Meeting in June.
T-DM1 is an anti-HER2 antibody–drug conjugate that 
combines emtansine (a cytotoxic agent) to trastuzumab to 
further increase the toxicity of the monoclonal antibody 
by targeting its activity directly to cancer cells.47 T-DM1 
administration improves progression-free survival and OS in 
the metastatic setting in case of trastuzumab-resistant HER2-
positive breast cancer.48,49 So far, no data are yet available in 
early-stage breast cancer, but the compound is actually being 
investigated in three Phase III trials.13 The KATHERINE 
study is comparing 14 cycles of adjuvant T-DM1 with trastu-
zumab in patients with residual disease following neoadjuvant 
chemotherapy combined with trastuzumab (NCT01772472). 
The KAITLIN trial is comparing the combination of T-DM1 
and pertuzumab with a taxane after surgery and anthracycline-
based chemotherapy (NCT01966471). Finally, the ATEMPT 
trial is comparing T-DM1 alone with paclitaxel plus trastu-
zumab followed by trastuzumab in stage I HER2-positive 
breast cancer (NCT01853748).
Neoadjuvant setting
The use of trastuzumab in the neoadjuvant setting of HER2-
positive early-stage breast cancer has revolutionized the man-
agement of these patients leading to the clinical development 
of new anti-HER2 targeted therapies in this setting.
The first of the large Phase III trials that supported the 
combination of trastuzumab and anthracycline-based che-
motherapy was the NOAH trial.50,51 The study included 
235 patients with locally advanced breast cancers and 
confirmed a beneficial effect of adding trastuzumab to 
chemotherapy in improving both pathological complete 
response (pCR) rate and survival outcomes. Subsequent 
studies confirmed that the addition of trastuzumab as part 
of neoadjuvant therapy significantly increases pCR with no 
additional toxicity and is currently the standard of care in this 
setting.52 As shown in the ACOSOG Z1041 trial, trastuzumab 
should be administered concurrently to taxane-based chemo-
therapy, while the administration with anthracyclines should 
be avoided.53 More recently, the HannaH trial validated the 
subcutaneous route of administration of trastuzumab as an 
alternative option.54–56
The combination of lapatinib and trastuzumab has been 
evaluated in multiple randomized trials.57 When combining 
the results from the six randomized studies that investi-
gated this combination, the dual blockade with trastuzumab 
and lapatinib was particularly active only in patients 
with hormone receptor-negative disease and treated with 
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taxane chemotherapy. Nevertheless, the increased pCR 
rates with the use of this combination did not translate in 
survival benefit.58
Pertuzumab has been evaluated in two Phase II neoad-
juvant trials (ie, NeoSphere and TRYPHAENA studies) in 
which patients received a combination of trastuzumab and 
chemotherapy with or without pertuzumab.59–61 As compared 
to the use of chemotherapy and trastuzumab alone, dual anti-
HER2 blockade with pertuzumab and trastuzumab was asso-
ciated with a significant improvement in pCR rate and a trend 
toward increased survival. Safety was confirmed with low 
rates of cardiac dysfunction in the investigational arms.
Neratinib in HER2-positive early-
stage breast cancer
Neratinib is an oral tyrosine kinase inhibitor that irreversibly 
inhibits HER1, HER2, and HER4 at the intracellular level.62,63 
This small molecule has shown promising results in both the 
metastatic and early settings including when administered 
to patients who have previously received trastuzumab-
based treatment.62,63
Adjuvant setting
Up to one-third of patients with HER2-positive early-stage 
breast cancer develop recurrent disease even when adequately 
treated.29,32 Hence, attempts to escalate the standard treat-
ment with chemotherapy and 1 year of trastuzumab should 
be considered of crucial importance for this subgroup of 
patients. Among these attempts, extending the duration of 
trastuzumab up to 2 years and the combination of trastuzumab 
and bevacizumab or lapatinib have failed.13 The ExteNET 
trial challenged another way to escalate treatment in this 
subgroup of patients by using neratinib at the completion of 
standard chemotherapy and 1 year of trastuzumab.64
The ExteNET study was a randomized, double-blind, 
placebo-controlled, Phase III trial that included a total of 
2,840 patients with HER2-positive stage I–III breast cancer 
who had previously completed 1 year of adjuvant trastu-
zumab. Eligible patients were randomized to an additional 
12 months of treatment with oral neratinib (240 mg/day) 
or matching placebo. Randomization was performed in a 
1:1 ratio and was generated with permuted blocks stratified 
by hormonal receptor status, nodal status, and trastuzumab 
mode of administration. A total of 31.5% of patients had 
tumors of #2 cm, 24% of them had node-negative disease, 
and 57% of the patients had hormone receptor-positive 
disease. After a median follow-up of 2 years, DFS was 
93.9% in the neratinib arm and 91.6% in the placebo arm, 
favoring the use of tyrosine kinase inhibitor (HR 0.67; 
95% CI 0.5–0.91; P=0.0091). The cumulative incidence 
of central nervous system recurrence was not different in 
the two arms (0.91% in the neratinib arm and 1.25% in the 
placebo arm, P=0.44), but longer follow-up is foreseen for 
acquiring better insight on this endpoint. The most common 
grade 3–4 adverse events in the neratinib arm included diar-
rhea (40%), vomiting (3%), and nausea (2%). Furthermore, 
patients reported to have an altered quality of life in the first 
month of treatment by neratinib followed by recovery toward 
baseline levels afterward.
Of note, in comparison to the HERA trial, which failed 
to show a DFS improvement by increasing anti-HER2 treat-
ment duration from 1 to 2 years, the ExteNET study enrolled 
patients with lower incidence of lymph node involvement 
(24 vs 32%, respectively) and administered more com-
monly trastuzumab with concurrent chemotherapy (62 vs 
0%, respectively) and more frequently the combination of 
anthracyclines and taxanes as adjuvant chemotherapy (68 vs 
26%, respectively). It is noteworthy also the presence of 
4.5 months between the end of trastuzumab and the initia-
tion of neratinib in the ExteNET trial, while this delay was 
not present in the HERA trial for trastuzumab initiation after 
chemotherapy (89 days). The authors attributed the posi-
tive results of the ExteNET trial to the oncogenic addiction 
of HER2-positive tumors to the HER2 pathway with the 
recurrence of breast cancer being secondary to an acquired 
resistance to trastuzumab that can lead to a possible re-
activation of the HER2 pathway after continuous inhibition. 
Adding neratinib would overcome this resistance especially 
in the absence of cross-resistance with trastuzumab. Interest-
ingly, a prespecified subgroup analysis of iDFS according 
to hormone receptor status showed that neratinib provided 
greater benefit to patients with hormone receptor-positive 
breast cancer (HR 0.51; 95% CI 0.33–0.77; P=0.0013) than 
to those with hormone receptor-negative tumors (HR 0.93; 
95% CI 0.6–1.43; P=0.74; P for interaction =0.054). Longer 
follow-up data from the study are awaited to better understand 
the potential role of neratinib in this setting.
In terms of toxicity, diarrhea is the most important side 
effect observed with the administration of neratinib (in the 
ExteNET trial, 55 and 40% of patients developed grade 1–2 
and grade 3–4 diarrhea, respectively).64 To overcome this 
issue, intensive loperamide prophylaxis during the first month 
of treatment has been shown to effectively reduce the occur-
rence of diarrhea and improves the overall tolerability to the 
drug.65 An open-label Phase II study is currently assessing 
the incidence and severity of diarrhea when routine use of 
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intensive loperamide prophylaxis is administered during the 
first month of neratinib therapy (NCT02400476).
Neoadjuvant setting
The I-SPY 2 TRIAL (Investigator of Serial Studies to Predict 
Your Therapeutic Response through Imaging and Molecular 
Analysis 2) is a Phase II “platform” trial with a backbone 
of standard therapy to which multiple experimental com-
pounds can be added and compared with a common control 
regimen.66 Patients with stage II–III breast cancer were 
included in the study with the only exception of women with 
hormone receptor-positive and low-risk tumors as assessed 
by the 70-gene assay. For the purpose of randomization, 
eligible patients were categorized into eight different sub-
types according to HER2 status, hormone receptor status, 
and genomic risk score. All patients received a neoadjuvant 
treatment with 12 cycles of weekly paclitaxel in the control 
group or in combination with one of the several experimen-
tal agents. Before surgery, all patients in all treatment arms 
received four cycles of doxorubicin and cyclophosphamide. 
The assignment to the experimental group was performed 
through an adaptive randomization procedure. With this 
approach, new patients entering the trial are more likely to 
be randomized to receive the compound that showed to be 
active for their specific tumor subtype. At the same time, this 
type of trial design allows a more rapid selection of promising 
regimens to be then developed in Phase III trials.66
One of the experimental therapy groups in the I-SPY 2 
trial evaluated the addition of neratinib.67 In this analysis, both 
patients with HER2-positive and -negative diseases could be 
included. Patients in the experimental arm received neratinib 
in addition to chemotherapy (n=115), while patients in the 
control group (n=78) received weekly paclitaxel alone if 
HER2 negative or with trastuzumab if HER2 positive. Nera-
tinib reached the predetermined threshold of efficacy with 
regard to patients with HER2-positive/hormone receptor-
negative disease. In these patients, the estimated rate of 
pCR was 56% in the neratinib group and 33% in the control 
group; the resulting probability that neratinib was superior to 
standard therapy was 95% and the probability of success in 
a Phase III trial including 300 patients was 79%. In patients 
with HER2-positive/hormone receptor-positive tumors, nera-
tinib also showed some evidence of superior activity. In these 
patients, the estimated rate of pCR was 30% in the neratinib 
group and 17% in the control group. This translated in a 91% 
probability of superiority of neratinib over standard therapy 
and a 65% predicted probability of success in a Phase III trial. 
When considering all patients with HER2-positive disease 
irrespective of hormone receptor status, the estimated rate of 
pCR was 39% in the neratinib group and 23% in the control 
group. The resulting probability that neratinib was superior 
to standard therapy was 95%, and the probability of success 
in a Phase III trial including 300 patients was 73%. There 
was limited activity of neratinib in patients with HER2-
negative disease independently of their hormonal receptor 
status, and the adaptive randomization algorithm stopped 
assigning these patients to receive the anti-HER2 tyrosine 
kinase inhibitor. Grade 3–4 treatment-related adverse events 
were mostly limited to diarrhea (38%) and were mitigated by 
dose reductions and/or symptomatic management. Results on 
survival from the I-SPY 2 trial are not mature yet.60
More recently, neratinib was also evaluated in the neo-
adjuvant NSABP FB 7 Phase II trial (NCT01008150).68 
This study had a backbone of weekly paclitaxel followed by 
doxorubicin and cylophosphamide. It included three arms 
consisting of trastuzumab, neratinib, or both added to pacli-
taxel. Preliminary results of this study have been reported 
at the San Antonio Annual Meeting in 2015. Overall, pCR 
rate was higher for the combination of trastuzumab and nera-
tinib (50.0%) in comparison to trastuzumab alone (38.1%) 
and neratinib alone (33.3%). The latter two results conflict 
with the I-SPY 2 trial in which neratinib was expected to 
be superior to trastuzumab. Final results from this study are 
awaited, including a longer follow-up to investigate possible 
survival difference among treatments.
Ongoing trials with neratinib in HeR2-
positive early-stage breast cancer
We conducted an electronic research of the registered trials 
until March 2017 using www.clinicaltrials.gov to identify the 
ongoing trials evaluating the role of neratinib in breast cancer. 
Our research yielded 23 registered trials, of which five trials 
included patients with early-stage breast cancer (Table 1).
Conclusion and future perspectives
More than 10 years have passed since the addition of 1 year 
trastuzumab to chemotherapy in the treatment of patients with 
HER2-positive early-stage breast cancer.2–4 Several efforts in 
trying to de-escalate or to escalate this approach have been 
investigated over the past years.13,69 For a specific subgroup of 
patients with node-negative and small tumors, de-escalating 
chemotherapy burden with the use of anthracycline-free 
regimen (weekly paclitaxel for 12 cycles) proved to be effec-
tive and can now be considered an option.70 In contrast, as 
further highlighted by long-term outcome results from the 
pivotal trastuzumab trials,29,32 ~25%–30% of women with 
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HER2-positive early-stage breast cancer still relapse at 
10 years. Further research efforts for trying to improve these 
outcomes should be considered as a research priority. Nera-
tinib has shown promising results in this setting demonstrating 
to be an active molecule in both the adjuvant and neoadju-
vant settings (Table 2). However, long-term follow-up 
data from the available trials as well as further studies are 
needed to better clarify its role in patients with HER2- 
positive early-stage breast cancer treated with trastuzumab- 
based therapy.
With the availability in the near future of another possible 
escalating strategy with the dual anti-HER2 blockade trastu-
zumab plus pertuzumab, the clinical management of patients 
with HER2-positive early-stage breast cancer may become 
even more challenging. In this scenario, translational research 
efforts should be prioritized in order to better identify which 
patients are not cured with chemotherapy plus trastuzumab. 
Predictive biomarkers beyond HER2 are also needed to better 
guide the preferred treatment option in these cases. So far, 
the main efforts in this field have focused on the potential 
role of HER2 receptor, PI3K, c-MYC expression, and the 
host immune system.
Several studies investigated the prognostic and/or pre-
dictive values of the HER2 gene polymorphisms,71 specific 
domains and alterations in the HER2 receptor,21,72–74 and 
soluble HER2 levels.75,76 However, no definitive conclusions 
can be drawn on this regard, especially for their predictive 
role in the adjuvant setting.
Table 1 Ongoing clinical trials with neratinib in early-stage breast cancer according to www.clinicaltrials.gov entries until March 2017
NCT number Phase Study title Subjects, n Status
NCT01008150 ii Phase ii randomized trial evaluating neoadjuvant therapy with neratinib 
and/or trastuzumab followed by postoperative trastuzumab in women with 
locally advanced HeR2-positive breast cancer
141 Active but 
not recruiting
NCT02400476 ii A study looking at the incidence and severity of diarrhea in patients with 
early-stage HeR2-positive breast cancer treated with neratinib and loperamide
240 Active and 
recruiting 
NCT00878709 iii Study evaluating the effects of neratinib after adjuvant trastuzumab in 
women with early stage breast cancer (exteNeT)
2,840 Active but 
not recruiting
NCT01042379 ii i-SPY 2 TRiAL: neoadjuvant and personalized adaptive novel agents to treat 
breast cancer (i-SPY 2)
1,920 Active and 
recruiting
NCT01008150 ii Phase ii randomized trial evaluating neoadjuvant therapy with neratinib 
and/or trastuzumab followed by postoperative trastuzumab in women with 
locally advanced HeR2-positive breast cancer
141 Active but 
not recruiting
Abbreviation: HeR2, human epidermal growth factor receptor 2.
Table 2 Available clinical trials with the use of neratinib in early-stage breast cancer
Trial Study 
design
Setting/
population 
Number 
of patients
Treatment arm Main results
exteNeT64 Phase iii Adjuvant setting/
stage i–iii breast 
HeR2-positive
1,420 CT + trastuzumab for 1 year + placebo for 
another year
2-year iDFS: 91.6%
1,420 CT + trastuzumab for 1 year + neratinib for 
another year
2-year iDFS: 93.9%
i-SPY 267 Phase ii Neoadjuvant setting/
stage ii/iii HeR2-
positive or -negativea
115 CT + neratinib pCR in HeR2-positive/eR-negative: 56%
pCR in HeR2-positive/eR-positive: 30%
pCR in HeR2-positive: 39%
78 Paclitaxel alone in HeR2-negative and with 
trastuzumab in HeR2-positive
pCR in HeR2-positive/eR-negative: 33%
pCR in HeR2-positive/eR-positive: 17%
pCR in HeR2-positive: 23%
NSABP FB 768 Phase ii Neoadjuvant setting/
stage iiB/iiiC HeR2-
positive
126 Paclitaxel + trastuzumab followed by 
doxorubicin and cylophosphamide
pCR: 38%
Paclitaxel + neratinib followed by 
doxorubicin and cylophosphamide
pCR: 33%
Paclitaxel + neratinib + trastuzumab followed 
by doxorubicin and cyclophosphamide
pCR: 50%
Note: aThere was limited activity of neratinib in patients with HeR2-negative disease independently of their hormonal receptor status, and the adaptive randomization 
algorithm stopped assigning these patients to receive the anti-HeR2 tyrosine kinase inhibitor.
Abbreviations: CT, chemotherapy; eR, estrogen receptor; HeR2, human epidermal growth factor receptor 2; iDFS, invasive disease-free survival; pCR, pathological 
complete response.
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Alterations that lead to constitutive activation of the PI3K 
pathway, including PI3K catalytic subunit alpha (PIK3CA) 
mutation and low PTEN expression, seem to be mediators 
of trastuzumab resistance.77 Several studies in both the 
metastatic78–80 and neoadjuvant81–83 settings appear to be in 
the same line of the findings from preclinical experiments. 
However, the available data in the adjuvant setting did not 
show any predictive role for PIK3CA or PTEN.84–87
The MYC oncoprotein acts as a downstream target of the 
proliferative signals driven by HER2 and has a potential role 
as predictor of response to anti-HER2-targeted therapies.88 
Although preliminary evidence suggested that MYC gene 
copy number abnormalities could be associated with addi-
tional benefit to trastuzumab even in the adjuvant setting,89 
subsequent research did not confirm the potential predictive 
role of MYC protein expression.90
Preclinical and clinical studies showed that the immune 
system gives a substantial contribution to the therapeutic effects 
of trastuzumab.91,92 Several studies have recently assessed 
the prognostic and predictive value of tumor-infiltrating 
lymphocytes (TILs).93–95 In the neoadjuvant setting, a recent 
large meta-analysis confirmed the association between pre-
treatment TIL levels and the probability of achieving pCR in 
patients with HER2-positive early-stage breast cancer treated 
with anti-HER2 agents.96 However, no association between 
TILs and pCR rates according to the type of administered 
anti-HER2 therapy (single or dual blockade) was observed.96 
In the adjuvant setting, data from the FinHER and NCCTG 
N9831 trials reported conflicting results on the role of TILs 
in predicting the benefit from trastuzumab.97,98 Hence, the role 
of TILs as contributors of the immune effects of trastuzumab 
antitumor activity remains controversial and needs to be 
further evaluated in patients with HER2-positive early-stage 
breast cancer.99 Immune gene signatures may be useful in 
this regard, by giving complementary information and more 
in depth insights on the immune functional status.99
The conflicting data in this field highlight the urgent 
need for further translational efforts in this setting from the 
clinical trials that have investigated the two anti-HER2 agents 
(ie, neratinib and pertuzumab) that proved to be of added 
benefit in patients already receiving standard chemotherapy 
plus trastuzumab for 1 year.
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